| 1.34 -0.04 (-2.9%) | 06-10 10:51 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.52 | 1-year : | 3.13 |
| Resists | First : | 2.15 | Second : | 2.68 |
| Pivot price | 1.63  |
|||
| Supports | First : | 1.3 | Second : | 1.08 |
| MAs | MA(5) : | 1.44 |
MA(20) : | 1.72 |
| MA(100) : | 3.54 |
MA(250) : | 43.29 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 6.8  |
D(3) : | 6 |
| RSI | RSI(14): 29.4 |
|||
| 52-week | High : | 270.25 | Low : | 1.3 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PPCB ] has closed above bottom band by 5.3%. Bollinger Bands are 74.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 187 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.45 - 1.46 | 1.46 - 1.47 |
| Low: | 1.36 - 1.37 | 1.37 - 1.38 |
| Close: | 1.37 - 1.38 | 1.38 - 1.39 |
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.
Fri, 05 Jun 2026
PPCB Should I Buy - Intellectia AI
Tue, 02 Jun 2026
How an ageing-science keynote ties into Propanc’s cancer trial - Stock Titan
Wed, 20 May 2026
Propanc pancreatic cancer drug saw 3 of 4 patients outlive life expectancy - Stock Titan
Fri, 15 May 2026
Propanc Biopharma, Inc. Reports Q3 Financial Results and Key Corporate Developments - Quiver Quantitative
Fri, 15 May 2026
Propanc moves to world-first cancer trial and anti-aging research - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 14.8 (%) |
| Held by Institutions | 0.8 (%) |
| Shares Short | 25 (K) |
| Shares Short P.Month | 8 (K) |
| EPS | 570.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.77 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -62.4 % |
| Return on Equity (ttm) | -127 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -8.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | 46 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 1.72 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.75 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|